Dublin, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The "International Directory of Generics Companies" directory has been added to ResearchAndMarkets.com's offering. This powerful directory is your connection ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

Oral anti-obesity formulations will be the next growth lever in Danish drugmaker Novo Nordisk's India strategy, following the 2025 launches of its blockbuster diabetes and obesity brands Ozempic and ...

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

Following its FDA approval in the summer, Tonix Pharma's fibromyalgia therapy Tonmya has been launched onto the market in the US, becoming the first new drug for the painful condition in more than 16 ...

Lupin Ltd. posted a 37.4 per cent year-on-year (YoY) jump in quarterly net profit to Rs. 1,180.5 crore in Q3 FY26, driven primarily by record US sales, stronger gross margins, and a favourable product ...

Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what’s been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Senators introduced legislation on Thursday that would ...

Feb 12 (Reuters) - West Pharmaceutical (WST.N), opens new tab forecast annual profit above Wall Street estimates on Thursday, banking on higher demand for diabetes and obesity treatments that use its ...

A brand-name drug is the original version of a medication that’s FDA-approved to treat a specific condition. Generics contain exact copies of the active ingredient in the original branded drug (an ...

Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics entering the marketplace and impact the company's sales.